Provention Bio, Inc.

Symbol: PRVB




Market price today

  • -30.3682

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 2.38B

    MRK Cap

  • 0.00%

    DIV Yield

Provention Bio, Inc. (PRVB) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Ashleigh W. Palmer B.Sc., M.B.A.
Full-time employees:174
City:Red Bank
Address:55 Broad Street

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

General Outlook

In simple terms, Provention Bio, Inc. has 95.093 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.956% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -5.986%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -5.313%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.260% return, is a testament to Provention Bio, Inc.'s adeptness in optimizing resource deployment. Provention Bio, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.461%. Furthermore, the proficiency of Provention Bio, Inc. in capital utilization is underscored by a remarkable -0.473% return on capital employed.

Stock Prices

Provention Bio, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $8.67, while its low point bottomed out at $8.19. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Provention Bio, Inc.'s stock market.

Liquidity Ratios

Analyzing PRVB liquidity ratios reveals its financial health of the firm. The current ratio of 193.22% gauges short-term asset coverage for liabilities. The quick ratio (184.05%) assesses immediate liquidity, while the cash ratio (48.72%) indicates cash reserves.

Current Ratio193.22%
Quick Ratio184.05%
Cash Ratio48.72%

Profitability Ratios

PRVB profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -589.90% underscores its earnings before tax deductions. The effective tax rate stands at 9.94%, revealing its tax efficiency. The net income per EBT, 90.06%, and the EBT per EBIT, 98.55%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -598.56%, we grasp its operational profitability.

Pretax Profit Margin-589.90%
Effective Tax Rate9.94%
Net Income per EBT90.06%
EBT per EBIT98.55%
EBIT per Revenue-598.56%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.93, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations.

Days of Sales Outstanding184
Days of Inventory Outstanding878
Operating Cycle920.44
Days of Payables Outstanding4820
Cash Conversion Cycle-3899
Receivables Turnover8.51
Payables Turnover0.08
Inventory Turnover0.42
Fixed Asset Turnover4.58
Asset Turnover0.05

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.43, and free cash flow per share, -0.44, depict cash generation on a per-share basis. The cash per share value, 2.21, showcases liquidity position. Lastly, the operating cash flow sales ratio, -2.76, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-0.43
Free Cash Flow per Share-0.44
Cash per Share2.21
Operating Cash Flow Sales Ratio-2.76
Free Cash Flow to Operating Cash Flow Ratio1.02
Cash Flow Coverage Ratio-1.34
Capital Expenditure Coverage Ratio-56.14
Dividend Paid and Capex Coverage Ratio-56.14

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 10.09%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.20, we discern the balance between debt and equity financing. The long-term debt to capitalization, 16.40%, and total debt to capitalization, 16.40%, ratios shed light on its capital structure. An interest coverage of -66.78 indicates its ability to manage interest expenses.

Debt Ratio10.09%
Debt Equity Ratio0.20
Long Term Debt to Capitalization16.40%
Total Debt to Capitalization16.40%
Interest Coverage-66.78
Cash Flow to Debt Ratio-1.34
Company Equity Multiplier1.94

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.17, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.52, reflects the portion of profit attributed to each share. The book value per share, 1.63, represents the net asset value distributed per share, while the tangible book value per share, 0.83, excludes intangible assets.

Revenue Per Share0.17
Net Income Per Share-1.52
Book Value Per Share1.63
Tangible Book Value Per Share0.83
Shareholders Equity Per Share1.63
Interest Debt Per Share0.33
Capex Per Share-0.01

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 769,693,110, captures the company's total value, considering both debt and equity. Income quality, 0.66, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 4.97, gauges operational efficiency, while the research and development to revenue, 587.86%, highlights investment in innovation. The ratio of intangibles to total assets, 25.15%, indicates the value of non-physical assets, and capex to operating cash flow, 1.05%, measures reinvestment capability.

Enterprise Value769,693,110
Income Quality0.66
Sales General and Administrative to Revenue4.97
Research and Development to Revenue587.86%
Intangibles to Total Assets25.15%
Capex to Operating Cash Flow1.05%
Capex to Revenue-6.17%
Capex to Depreciation-64.74%
Stock-Based Compensation to Revenue147.56%
Graham Number7.47
Return on Tangible Assets-64.05%
Graham Net Net0.69
Working Capital84,259,000
Tangible Asset Value62,288,000
Net Current Asset Value59,642,000
Average Receivables679,500
Average Payables5,153,500
Average Inventory615,500
Days Sales Outstanding38
Days Payables Outstanding4820
Days of Inventory On Hand878

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 15.32, and the price to book ratio, 15.32, reflect the market's valuation relative to the company's book value. The price to sales ratio, 205.33, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -73.06, and price to operating cash flows, -58.44, gauge market valuation against cash flow metrics.

Price Book Value Ratio15.32
Price to Book Ratio15.32
Price to Sales Ratio205.33
Price Cash Flow Ratio-58.44
Enterprise Value Multiple-36.16
Price Fair Value15.32
Price to Operating Cash Flow Ratio-58.44
Price to Free Cash Flows Ratio-73.06
Price to Tangible Book Ratio6.48
Enterprise Value to Sales59.69
Enterprise Value Over EBITDA-6.17
EV to Operating Cash Flow-10.21
Earnings Yield-14.38%
Free Cash Flow Yield-9.65%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Provention Bio, Inc. (PRVB) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -30.368 in 2024.

What is the ticker symbol of Provention Bio, Inc. stock?

The ticker symbol of Provention Bio, Inc. stock is PRVB.

What is company IPO date?

IPO date of Provention Bio, Inc. is 2018-07-24.

What is company current share price?

Current share price is 24.980 USD.

What is stock market cap today?

The market cap of stock today is 2375415796.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 174.